Azopharma Product Development Group And ACCU-BREAK Pharmaceuticals, Inc. Announce Strategic Alliance Partnership

Privately-held Azopharma Product Development Group, Inc. ("Azopharma") and ACCU-BREAK Pharmaceuticals, Inc. ("ABP") announced recently the signing of a strategic alliance agreement in which Azopharma will become the "center of excellence" for developing products based on ABP's innovative ACCU-BREAK patented tablet technologies which allow for accurate and individualized dosage adjustment.

Dr. Allan Kaplan, CEO of ABP stated, "ABP's patented ACCU-BREAK technologies create an inactive break layer in tablets allowing them to be broken into accurate partial doses. By breaking at the inactive layer, accurate dose splitting can be guaranteed, since the active layer remains undisturbed. The ACCU-BREAK technologies have important implications for pharmaceutical companies as well as physicians and their patients." Phil Meeks, CEO of Azopharma commented, "These new patented technologies will help pharmaceutical companies in many ways. From creating new products utilizing these novel technologies to gaining competitive market share by modifying existing products, we expect the pharmaceutical companies to be greatly affected by the ACCU-BREAK technologies."

For pharmaceutical companies, the ACCU-BREAK technologies also provide a solution for formulation challenges such as separating incompatible active ingredients to allow for the development of unique combination therapy products. For physicians, the ACCU-BREAK technologies allow for greater flexibility in dose adjustment and greater safety in the dose titration process. For patients, the ACCU-BREAK technologies are designed to assist them in following dosing instructions for splitting tablets with ease and accuracy.

Mr. Meeks continued, "We are excited to be the center of excellence for the development of products using ACCU-BREAK technologies. Our expertise in formulation and in total product development makes us the ideal partner for ABP."

Azopharma & ACCU-BREAK Strategic Alliance Highlights:

• ACCU-BREAK technologies are U.S. patented until at least 2025.
• Strategic alliance agreement for five years between Azopharma Product Development Group and ACCU-BREAK Pharmaceuticals, Inc.
• Azopharma Product Development Group provides sales and marketing support for ACCU-BREAK technologies for five years.
• Patented tablet technologies provide solutions for pharmaceutical companies as well as physicians and patients in overcoming issues associated with tablet breaking and dose splitting.

Azopharma Company Capabilities and Services:

• Azopharma Contract Pharmaceutical Services - Integrated product development and CTM manufacturing for all dosage forms.
• ApiCross Drug Delivery Technologies - Proprietary drug delivery platforms to solve difficult molecular challenges.
• Cyanta Analytical Laboratories - Analytical chemistry and inhalation services from development to quality control testing.
• AniClin Preclinical Services - Preclinical services in support of early product development.
• IQsynthesis - Synthetic chemistry services from discovery to clinical API supplies including large scale API synthesis.
• AvivoClin Clinical Services - Human clinical pharmacology services for Phase I/II/III clinical trials.

Mr. Meeks concluded, "Azopharma Product Development Group is only one of a few organizations in the U.S. that are capable of developing a full spectrum of dosage forms from discovery through clinical trial manufacturing. By bringing together the best scientists in the field, state-of-the-art facilities and our focus on quality means that we can provide our partners a winning combination in product development."

About Azopharma
Azopharma Product Development Group is FDA registered, DEA approved and client audited on a regular basis. Azopharma's mission is to help our customers turn Ideas Into Cures . In product development, it comes down to the right people, their commitment and application of experience. Partnering with Azopharma provides customers with the confidence of assured success. We welcome visits to our facility in Miramar, FL and our other sites to conduct audits or meet with our pharmaceutical scientists to outline a study that meets your specific needs. Contact us at development@azopharma.com .

About ACCU-BREAK Pharmaceuticals, Inc.
ABP is developing ACCU-BREAK technologies for pharmaceutical tablets. The Company believes that these technologies may allow physicians to better customize treatment for their patients and that tablets utilizing ACCU-BREAK technologies will represent improved dosage forms for many types of medications.

SOURCE: Azopharma Product Development Group, Inc. and ACCU-BREAK Pharmaceuticals, Inc.